Table 1.
CD40/CD154 blockade in nonhuman primate transplant models.
| Drug name | Type of transplant | Main findings |
|---|---|---|
| CD154 blockade | ||
|
| ||
| hu5C8 | Kidney [88,89] | Prolonged graft survival (alone or combined with CTLA4-Ig ) |
| Islet [90,91] | Prolonged graft survival | |
| Skin [92] | Prolonged graft survival | |
| Heart [93] and unpublished data | Prolonged graft survival | |
| Attenuated CAV (combined with selective CD28 blockade) | ||
|
| ||
| IDEC-131 | Kidney [94] | Prolonged graft survival |
| Synergize with rapamycin/DST operational tolerance | ||
| Skin [95] | Prolonged graft survival (combined with rapamycin) | |
| Heart [96,97] | Prolonged graft survival | |
| Less potent and efficacious than hu5C8 | ||
|
| ||
| ABI793 | Kidney [98,99] | Prolonged graft survival |
|
| ||
| H106 | Kidney [100] | Prolonged graft survival (combined with CTLA4-Ig) |
|
| ||
| CD40 blockade | ||
|
| ||
| Ch5D12 (chimeric) | Kidney [101] | Prolonged graft survival (alone or combined with anti-CD86 mAb) |
|
| ||
| Chi220 (chimeric) | Kidney [100] | Prolonged graft survival |
| Suppress donor-specific Abs (combined with CTLA4-Ig ) | ||
| Islet [102] | Prolonged graft survival | |
| Synergize with belatacept | ||
|
| ||
| ASKP1240 (4D11) | Kidney [103] | Prolonged graft survival |
| Islet [104] | Prolonged graft survival | |
| Liver [105] | Prolonged graft survival | |
|
| ||
| 3A8 | Islet [106,107] | Prolonged graft survival (combined with basiliximab/sirolimus) |
| Additional CTLA4-Ig suppress alloantibody | ||
| Bone marrow [108] | Prolonged chimerism (combined with CTLA4-Ig/sirolimus) | |
|
| ||
| 2C10R1 | Islet [109] | Prolonged graft survival (combined with basiliximab/sirolimus) |
|
| ||
| 2C10R4 | Islet [109] | Prolonged graft survival (combined with basiliximab/sirolimus) |
| Heart [110] | Prolonged graft survival | |
CAV: Cardiac allograft vasculopathy; DST: Donor-specific transfusion.